TECOmedical and Quidel in a strategic partnership offer an extensive range of FDA and EMA approved biomarkers for pre-clinical and clinical studies related to the Complement system. Biomarkers for biosafety studies: Hemocompatibility and CARPA related to activation of the complement-C system in human and animal models, Cytotoxicity and drug-induced liver and kidney injury testing. Apoptosis and proliferation assays for Anti-Cancer Agent testing. Furthermore, TECOmedical offers customized test development: ADA, immunogenicity and host cell protein assays. www.tecomedical.com
Exsera BioLabs is a specialized complement laboratory uniquely qualified to take on your drug development needs. Our depth of experience allows us to understand not just the complexities of complement testing, but also how to navigate the intricacies to make sure you have the testing most appropriate to your study needs. Exsera is CAP/CLIA certified and GXP compliant. We are committed to providing quality, timely results with the Insight and expertise that makes a difference.
Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. Our mission is to create progress for patients where they need it most and our hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades.